These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7072211)

  • 41. [New inotropic agents in the treatment of congestive heart failure].
    Hutton I; McKillop J; Clark R; Martin W; Tweddel A
    Ter Arkh; 1982; 54(11):98-101. PubMed ID: 7157176
    [No Abstract]   [Full Text] [Related]  

  • 42. [Positive inotropic effect of coronary-active drug: oxyfedrine].
    Conti G; Moreschini G; Pelosi M
    Minerva Cardioangiol; 1980 Sep; 28(9):645-7. PubMed ID: 7465070
    [No Abstract]   [Full Text] [Related]  

  • 43. Growth hormone in end-stage heart failure.
    Dreifuss PM
    Lancet; 1997 Jun; 349(9068):1841-2; author reply 1843. PubMed ID: 9269240
    [No Abstract]   [Full Text] [Related]  

  • 44. [On the advantages of the use of desacetyl-lanatoside C in cardiokinetic therapy].
    De Magistris L; Menegazzo G
    Minerva Med; 1967 Feb; 58(13):482-8. PubMed ID: 6021619
    [No Abstract]   [Full Text] [Related]  

  • 45. [Fendiline for hypodynamic coronary heart disease patients. Calmodulin antagonists--alternatives to calcium antagonism].
    Fortschr Med; 1985 Oct; 103(40):64. PubMed ID: 4065792
    [No Abstract]   [Full Text] [Related]  

  • 46. [Perspectives for enalapril in the therapy of coronary heart disease. European Cardiology Symposium, Montreux, February 1997].
    Dtsch Med Wochenschr; 1997; 122(21 Suppl Perspektiv):1-8. PubMed ID: 9439478
    [No Abstract]   [Full Text] [Related]  

  • 47. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
    Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
    Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy of ischemic and nonischemic heart failure. Current status and prospects].
    Weil J; Riegger G
    Internist (Berl); 2002 Apr; 43 Suppl 1():S8, S11-8. PubMed ID: 11993003
    [No Abstract]   [Full Text] [Related]  

  • 49. Growth hormone treatment in chronic heart failure: lessons from the first 99 patients.
    Cicoira M; Coats AJ; Anker SD
    Eur Heart J; 1998 Nov; 19(11):1605-7. PubMed ID: 9857911
    [No Abstract]   [Full Text] [Related]  

  • 50. [Neoton (exogenic phosphocreatinine) in combined therapy of chronic cardiac failure].
    Nedoshivin AO; Perepech NB
    Klin Med (Mosk); 1996; 74(9):45-8. PubMed ID: 9121090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacodynamic aspects of obzidan in chronic ischemic heart disease].
    Zaĭtseva VI; Dorogoĭ AP
    Ter Arkh; 1982; 54(11):123-8. PubMed ID: 7157162
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiac performance: growth hormone enters the race.
    Saccà L; Fazio S
    Nat Med; 1996 Jan; 2(1):29-31. PubMed ID: 8564831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Serum protein binding of salicylates in chronic circulatory insufficiency].
    Tikhonov VP
    Ter Arkh; 1972 Apr; 44(4):83-6. PubMed ID: 5051563
    [No Abstract]   [Full Text] [Related]  

  • 54. The potential for growth hormone in the management of heart failure.
    Monson JP; Besser GM
    Heart; 1997 Jan; 77(1):1-2. PubMed ID: 9038681
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiac failure responding to growth hormone.
    Cuneo RC; Wilmshurst P; Lowy C; McGauley G; Sönksen PH
    Lancet; 1989 Apr; 1(8642):838-9. PubMed ID: 2564917
    [No Abstract]   [Full Text] [Related]  

  • 56. [Therapeutic scheme for arteriosclerotic coronary cardiopathy].
    Sacchetti C
    Cardiol Prat; 1970 Apr; 21(2):63-7. PubMed ID: 5494835
    [No Abstract]   [Full Text] [Related]  

  • 57. [State of several hemodynamic indices in patients with chronic circulatory insufficiency and their changes under the effects of cardiotonic therapy].
    Mileshin PIa; Klykov NV
    Ter Arkh; 1970 Nov; 42(11):48-51. PubMed ID: 5532722
    [No Abstract]   [Full Text] [Related]  

  • 58. [More and more complicated combination therapy of ischemic heart disease].
    Erhardt L; Herlitz J; Näslund U; Persson S
    Lakartidningen; 1989 Dec; 86(52):4595-7. PubMed ID: 2607868
    [No Abstract]   [Full Text] [Related]  

  • 59. Growth hormone and proinflammatory cytokine activation in heart failure. Just a new verse to an old sirens' song?
    Wollert KC; Drexler H
    Eur Heart J; 2003 Dec; 24(24):2164-5. PubMed ID: 14659767
    [No Abstract]   [Full Text] [Related]  

  • 60. [It is of importance to emphasize the optimal drug therapy in patients with chronic heart failure].
    Wu XS; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):24-5. PubMed ID: 21418791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.